New treatment for advanced liver cancer after other therapies stopped working
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new medication called YMN-A02 for people with advanced liver cancer that has not responded to standard targeted and immunotherapy treatments. The goal is to see if this new drug can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your liver cancer is advanced and has continued to grow after you've had both targeted therapy (like sorafenib or lenvatinib) and immunotherapy (like pembrolizumab or nivolumab).
- You have at least one measurable tumor on scans (at least 1 cm in size).
- You are generally able to care for yourself and do light activities (ECOG 0-1).
- Your blood counts, liver, and kidney function are within certain limits, and your heart is pumping well (LVEF >= 50%).
- You have not had an mRNA vaccine (like some COVID vaccines) or been in a trial with LNP formulations before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of two treatments for advanced liver cancer that cannot be removed by surgery. One treatment delivers chemotherapy directly to the tumor, and the other uses tiny beads to block the tumor's blood supply. This approach may help shrink tumors and slow the cancer's growth.
This study tests two new immunotherapy drugs (JS207 and JS007) as a first treatment for advanced liver cancer. It might be an option if you have not had any prior cancer medicine and your liver tumor is not blocking the main portal vein.
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.